NKGen Biotech, Inc. Warrants
NKGen Biotech, Inc. operates as a clinical-stage biotechnology company that focuses on the development and commercialization of autologous, allogeneic, and CAR-NK natural killer cell therapies. Its lead products include SNK01, an autologous NK cell therapy candidate treatment for neurodegenerative diseases; and SNK02, an allogeneic NK cell therapy, which is in Phase 1 clinical trials for refracto… Read more
NKGen Biotech, Inc. Warrants (NKGNW) - Total Liabilities
Latest total liabilities as of June 2024: $85.36 Million USD
Based on the latest financial reports, NKGen Biotech, Inc. Warrants (NKGNW) has total liabilities worth $85.36 Million USD as of June 2024.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
NKGen Biotech, Inc. Warrants - Total Liabilities Trend (2021–2023)
This chart illustrates how NKGen Biotech, Inc. Warrants's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
NKGen Biotech, Inc. Warrants Competitors by Total Liabilities
The table below lists competitors of NKGen Biotech, Inc. Warrants ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Multi Retail Group Ltd
TA:MRG
|
Israel | ILA672.04 Million |
|
Thor Mining PLC
PINK:THORF
|
USA | $208.00K |
|
DELPHI AUTOMOTIVE
BE:D7A
|
Germany | €15.57 Billion |
|
Jade Leader Corp
PINK:MCKRF
|
USA | $453.20K |
|
REALTY
MU:RY6
|
Germany | €29.15 Billion |
|
ACME Lithium Inc
OTCQB:ACLHF
|
USA | $468.23K |
|
AXIS SP GDR REG-S (UZC.SG)
STU:UZC
|
Germany | €13.79 Trillion |
Liability Composition Analysis (2021–2023)
This chart breaks down NKGen Biotech, Inc. Warrants's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 0.02 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | -1.22 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 5.46 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how NKGen Biotech, Inc. Warrants's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for NKGen Biotech, Inc. Warrants (2021–2023)
The table below shows the annual total liabilities of NKGen Biotech, Inc. Warrants from 2021 to 2023.
| Year | Total Liabilities | Change |
|---|---|---|
| 2023-12-31 | $75.17 Million | +409.07% |
| 2022-12-31 | $14.77 Million | -73.69% |
| 2021-12-31 | $56.12 Million | -- |